According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “
A number of other brokerages have also recently issued reports on OBSV. HC Wainwright decreased their price objective on shares of ObsEva from $23.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, January 4th. JPMorgan Chase & Co. cut shares of ObsEva from a “neutral” rating to an “underweight” rating in a research note on Monday, November 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $10.21.
Shares of NASDAQ:OBSV opened at $2.11 on Tuesday. The company’s 50 day simple moving average is $2.10 and its 200 day simple moving average is $2.55. The stock has a market capitalization of $101.28 million, a price-to-earnings ratio of -0.85 and a beta of 1.00. The company has a debt-to-equity ratio of 1.14, a current ratio of 2.06 and a quick ratio of 2.06. ObsEva has a 1 year low of $1.63 and a 1 year high of $6.30.
ObsEva (NASDAQ:OBSV) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.15). As a group, analysts anticipate that ObsEva will post -1.79 EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the business. Jane Street Group LLC acquired a new stake in ObsEva in the third quarter valued at approximately $27,000. GSA Capital Partners LLP acquired a new stake in ObsEva in the third quarter valued at approximately $38,000. Schonfeld Strategic Advisors LLC acquired a new stake in ObsEva in the third quarter valued at approximately $114,000. State Street Corp acquired a new stake in ObsEva in the third quarter valued at approximately $124,000. Finally, California Public Employees Retirement System acquired a new stake in ObsEva in the second quarter valued at approximately $401,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
Recommended Story: Analyst Ratings Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.